Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response

摘要

>What is already known about this subject class="unordered" style="list-style-type:disc">The pharmacokinetics of alemtuzumab have been incompletely described to date.At most, presentations of half-life have been reported in clinical articles using data at the individual level.>What this paper adds class="unordered" style="list-style-type:disc">This paper presents a comprehensive population pharmacokinetic–pharmacodynamic model for alemtuzumab in B-CLL patients using lymphocyte counts as the biomarker and links the model to clinical outcomes.AimsTo characterize alemtuzumab pharmacokinetics and its exposure–response relationship with white blood cell (WBC) count in patients with B-cell chronic lymphocytic leukaemia (CLL).